Tim Rea

Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to develop new therapies for age-driven diseases. Cell aging is the primary, underlying driver for many of today’s major diseases, but is yet to be truly leveraged as a therapeutic target. Operating at the intersection of machine learning and cell biology, Shift’s narrow-AI approach leverages large-scale, proprietary multiomic datasets to uncover the hidden biology of cell aging and rejuvenation. Through this, the Company has built a robust pipeline of rejuvenation targets, including SB000 – a novel, single-gene target capable of cell rejuvenation across multiple cell types. Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO. The Company is based at the Gurdon Institute, Cambridge thanks to the Frame Shift bio-incubator, an initiative of the Milner Therapeutics Institute, and has additional computational facilities in Toronto, Canada.

We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.

Safe, sterile endoscopy. Anywhere. Meet patient demand with IQ Endoscopes range of single-use, high performance flexible endoscopes.

Crypto Quantique is building the most secure end-to-end IoT security platform. We are a transformative cybersecurity technology company, using the most advanced techniques in cryptography and quantum physics, designed to ensure that both device security becomes foundational and end-to-end IoT security standard practice. Crypto Quantique has proven the worlds first quantum driven security on a chip and its IP can generate multiple, unique, unforgeable cryptographic keys that never need to be stored and used independently by multiple applications on demand. When combined with their cryptographic APIs and key management system the solution creates a natural bridge between silicon, device, software and solutions providers. Crypto Quantique’s technology products, platforms, and services provide the strongest end-to-end security throughout any IoT network. Our quantum driven cybersecurity design overcomes existing state-of-the art limitations by providing: • Quantum driven security foundation offering a complete solution for identifying, securing and managing IoT devices while reducing cost and lowering risk. • Very high entropy multi-use, unforgeable, tamper resistant cryptographic keys generated on-demand direct from silicon using quantum tunneling. • Quantum-safe derived keys, futureproofing IoT security. • Cloud ready multi-use Key Management System offering frictionless device enrollment and zero-trust, zero-touch provisioning and ongoing lifecycle management. Crypto Quantique was founded by technologists and visionaries Dr. Shahram Mossayebi, PhD in post-quantum cryptography and Dr. Patrick Camilleri, PhD in microelectronics engineering and complex systems.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients. We realise that we can’t progress our mission alone, and so are committed to forging a new model of drug discovery, working in partnership across both academia and industry to realise this vision. We are committed to being an open, inclusive and responsible company, PhoreAll and PhorEST being our dedicated inclusion and green initiatives. Please contact us to learn more: https://www.phoremost.com/contact

Entia is making life better for people receiving cancer treatment. We develop a range of virtual oncology solutions comprising novel self-testing blood analysers, apps and digital health solutions that seamlessly integrate with healthcare systems. Our ambitious team works on patient-centric designs, innovative technology and cutting edge medical science. Through these, we are redefining cancer care to empower patients and physicians, and benefit the wider global healthcare community.

TidalSense, formerly Cambridge Respiratory Innovations, is a venture-backed respiratory technology company headquartered in Cambridge UK. TidalSense builds AI-driven diagnostic and monitoring solutions for respiratory medicine built on the foundation of the companys novel patented sensor technology, N-Tidal, which provides unprecedented insight into lung physiology through high accuracy, rapid sampled CO2, unlike anything seen before in clinical medicine.

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells (HLCs) with functional relevance comparable to human primary cells. Our HLCs effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our HLCs successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.

At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPject™ could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx Youtube: Phico Therapeutics Ltd

We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed loop models of care. To learn more about our mission to deliver #PrecisionCareForAll, please visit: www.closedloopmedicine.com

PredictImmune develops pioneering tools for guiding personalised treatment options in immune-mediated diseases such as inflammatory bowel disease (IBD). Based on world-leading research at Cambridge University, UK, we are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payers all recognise the value of such an approach to the management of inflammatory bowel disease (IBD). www.predictimmune.com

SPOKE is a vertically integrated online menswear brand. We use an e-commerce model to give men exactly what theyre looking for: properly made clothes that really fit, without the luxury markup. Our clothes are cut in more sizes, from the very best fabric and trim - then sold direct to the consumer, at a sane price. Find us at www.spoke-london.com.

Managing global payments complexity for SaaS and digital product companies. We’re the Merchant of Record that helps you get paid from anywhere and grow everywhere. Paddle manages global payments complexity for SaaS and digital product companies, so you don’t have to. Paddle operates as a Merchant of Record, managing global payments and currencies, fraud, customer billing support, and complying with every local sales tax rule on your behalf. That’s your operational needs handled. To truly scale everywhere, Paddle gives you insight into your revenue metrics, benchmarks your performance and gives you the tools and expert advice to accelerate your growth. Were proud to serve over 4000 software and digital product companies, backed by world-class investors including KKR, FTV Capital, Kindred, Notion, and 83North. Get paid from anywhere, grow everywhere with Paddle.

Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to develop new therapies for age-driven diseases. Cell aging is the primary, underlying driver for many of today’s major diseases, but is yet to be truly leveraged as a therapeutic target. Operating at the intersection of machine learning and cell biology, Shift’s narrow-AI approach leverages large-scale, proprietary multiomic datasets to uncover the hidden biology of cell aging and rejuvenation. Through this, the Company has built a robust pipeline of rejuvenation targets, including SB000 – a novel, single-gene target capable of cell rejuvenation across multiple cell types. Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO. The Company is based at the Gurdon Institute, Cambridge thanks to the Frame Shift bio-incubator, an initiative of the Milner Therapeutics Institute, and has additional computational facilities in Toronto, Canada.

We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.

Safe, sterile endoscopy. Anywhere. Meet patient demand with IQ Endoscopes range of single-use, high performance flexible endoscopes.

Crypto Quantique is building the most secure end-to-end IoT security platform. We are a transformative cybersecurity technology company, using the most advanced techniques in cryptography and quantum physics, designed to ensure that both device security becomes foundational and end-to-end IoT security standard practice. Crypto Quantique has proven the worlds first quantum driven security on a chip and its IP can generate multiple, unique, unforgeable cryptographic keys that never need to be stored and used independently by multiple applications on demand. When combined with their cryptographic APIs and key management system the solution creates a natural bridge between silicon, device, software and solutions providers. Crypto Quantique’s technology products, platforms, and services provide the strongest end-to-end security throughout any IoT network. Our quantum driven cybersecurity design overcomes existing state-of-the art limitations by providing: • Quantum driven security foundation offering a complete solution for identifying, securing and managing IoT devices while reducing cost and lowering risk. • Very high entropy multi-use, unforgeable, tamper resistant cryptographic keys generated on-demand direct from silicon using quantum tunneling. • Quantum-safe derived keys, futureproofing IoT security. • Cloud ready multi-use Key Management System offering frictionless device enrollment and zero-trust, zero-touch provisioning and ongoing lifecycle management. Crypto Quantique was founded by technologists and visionaries Dr. Shahram Mossayebi, PhD in post-quantum cryptography and Dr. Patrick Camilleri, PhD in microelectronics engineering and complex systems.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic